Acurx Pharmaceuticals (Nasdaq: ACXP) (Acurx or the Company), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections ...

Faecal transplants can boost the immune systems of patients with advanced cancer, improving their response to immunotherapy.

Rodents fed a diet high in soluble fiber showed improved resistance to a microorganism that causes diarrhea and can be fatal ...

TEDCO, Maryland's economic engine for technology companies, announced the next round of Maryland Innovation Initiative ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial ...

A new study shows that the simple application of computerized provider order entry prompts can reduce the use of unnecessary ...

New data includes real-world analyses of VOQUEZNA-treated patients in the U.S. diagnosed with gastroesophageal reflux disease (GERD) </ ...

The ongoing trial is testing the therapy – RBX2660 – as a treatment for Clostridioides difficile infection or C. diff, a bacterium that causes diarrhoea and inflammation in the colon and is a ...

C. difficile infection causes severe diarrhea, which can lead to sepsis (generalized infection) and even death. Many strains are resistant to existing drugs, making treatment difficult.

A research team at the University of Nottingham has received £1.3 million from the Medical Research Council (MRC) to develop ...

It is sad to see pets die of something easily preventable. It's even worse knowing that the owner was misinformed or misled ...

It helps you build strength,' how playing football helped one CSU Pueblo student athlete beat cancer and return to the field.